MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Pulmonology, Respiratory
MannKind Corporation (NASDAQ: MNKD)*
Organization & Developments: MannKind
Parents
MannKind Corporation (NASDAQ: MNKD)*
Children
*MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic p
*Technosphere® Insulin System, consists of a proprietary dry powder formulation of insulin that is inhaled into the deep lung usi
14. MannKind - $108.95M (€79.1) 2010 R&D
2016: Why MannKind Is Heading Towards Bankruptcy - MannKind Corporation (NASDAQ:MNKD)
2018: FDA Issues Warning To MannKind After Report Of Misbranding - MannKind Corporation (NASDAQ:MNKD)
2019: MannKind - Scripts, IndyCar And Poster Presentation - MannKind Corporation (NASDAQ:MNKD)
2022: Mannkind Corporation: Ready For Your Biotech Portfolio_seekingalpha.com
2022: MannKind Is Poised To Turn A Profit And Shares Could Get Cheaper_seekingalpha.com
2023: Tyvaso DPI Is Breathing New Life Into MannKind's Balance Sheet (Rating Upgrade)_ seekingalpha
2024: MannKind advances phase 3 NTM lung disease study By Investing.com
2024: MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
2024: MannKind Corporation: Finally Gaining Traction
2024: MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
2024: MannKind reports positive data for inhaled insulin for children
2024: MannKind's inhaled insulin meets primary efficacy endpoint in study
2024: MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
2025: MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
2025: MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition
Jumps
*Key People: Mannkind
Finance & Acquisitions: MannKind